Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536784 | 0.98 | L3MBTL1 (0.42) | MEN1KMT2APDK2ACHEL3MBTL1 | |
| SCHEMBL8536520 | 0.98 | L3MBTL1 (0.42) | MEN1KMT2APDK2ACHEL3MBTL1 | |
| SCHEMBL8560891 | 0.98 | KMT2A (0.44) | MEN1KMT2APDK2ACHEADRA1B | |
| SCHEMBL8561001 | 0.98 | L3MBTL1 (0.42) | MEN1KMT2APDK2ACHEL3MBTL1 | |
| SCHEMBL8559600 | 0.98 | KMT2A (0.44) | MEN1KMT2APDK2ACHEADRA1B | |
| SCHEMBL8589316 | 0.97 | KMT2A (0.43) | MEN1KMT2APDK2L3MBTL1ADRA1B | |
| SCHEMBL8561128 | 0.97 | KMT2A (0.43) | MEN1KMT2APDK2L3MBTL1ADRA1B | |
| SCHEMBL8541603 | 0.96 | PDK2 (0.43) | MEN1KMT2APDK2ACHEL3MBTL1 | |
| SCHEMBL8560998 | 0.95 | ADRA1B (0.42) | MEN1KMT2APDK2ACHEL3MBTL1 | |
| SCHEMBL8561376 | 0.95 | KMT2A (0.47) | MEN1KMT2APDK2ADRA1BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993559-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993559-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9351484-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351484-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012068001-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | MEN1 2038/4885KMT2A 3225/4885PDK2 3856/4885 |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | MEN1 2038/4885KMT2A 3225/4885PDK2 3856/4885 |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | MEN1 2038/4885KMT2A 3225/4885PDK2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.